Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 15/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | SOAT2 | O75908 | 2/20 | 0.50 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.50 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10259896 | 0.94 | DGAT1 (0.69) | DGAT1CYP2C9TP53THRBMAPT | |
| SCHEMBL410736 | 0.94 | DGAT1 (0.69) | DGAT1CYP2C9TP53THRBMAPT | |
| SCHEMBL10198110 | 0.94 | DGAT1 (0.69) | DGAT1CYP2C9TP53THRBMAPT | |
| SCHEMBL10197384 | 0.83 | DGAT1 (0.86) | DGAT1MAPTSOAT2 | |
| SCHEMBL10197345 | 0.79 | DGAT1 (0.89) | DGAT1CYP2C9SOAT2SOAT1DGAT2 | |
| SCHEMBL405505 | 0.77 | DGAT1 (1.00) | DGAT1CYP2C9SOAT2SOAT1DGAT2 | |
| SCHEMBL405504 | 0.77 | DGAT1 (1.00) | DGAT1CYP2C9SOAT2SOAT1DGAT2 | |
| SCHEMBL12045611 | 0.77 | DGAT1 (0.90) | DGAT1CYP2C9TP53THRBMAPT | |
| SCHEMBL12045656 | 0.76 | DGAT1 (0.65) | DGAT1CYP2C9TP53THRBMAPT | |
| SCHEMBL10198345 | 0.76 | DGAT1 (0.88) | DGAT1CYP2C9SOAT2SOAT1DGAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022057-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE | SCHERING CORPORATION (US) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022057-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE | DGAT2, DGAT1, LCAT | DGAT1 2/4885CYP2C9 1475/4885TP53 4414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.